ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login

2021 - Wearable Bolus Injectors: Balancing Stakeholder Needs and Overcoming Barriers to Entry

Date2021-07-29

Deadline2021-07-29

VenueXtalks, Canada Canada

KeywordsBiologics; Wearable Injectors; Immune-Oncology

Websitehttps://xtalks.com/webinars/bolus-wearab...s-to-entry

Topics/Call fo Papers

Until now, biologics and immuno-oncology drugs have tended to fall into two very different delivery modalities: 1 ml to 2 ml self-administered injection using devices such as autoinjectors and 10ml+ infusion delivery typically administered by healthcare professionals in a hospital or outpatient setting. More and more, pharmaceutical companies are formulating (or re-formulating) drugs that fall into the gap between these modalities, in the drive to move the delivery of higher-volume biologics away from the clinic and towards a home-based, self-administered environment. This creates opportunities for subcutaneous injection devices that can deliver volumes beyond the reach of current autoinjectors and those of current infusion devices.
Although the number of commercially available on-body delivery systems remains low, several companies have devices in development to help fill this gap, including the recent collaboration announced between Phillips-Medisize and Subcuject. However, the market for such devices remains in its infancy and faces persistent challenges from well-established autoinjectors and a new cohort of larger payload, more sustainable autoinjector variants.
Launched devices and those in development range from simple piston-based systems to sophisticated electromechanical devices, employing drug containers ranging from fill at point-of-use custom-designed reservoirs to industry-standard primary containers. With uncertainty over the patient acceptance of wearable devices and no precedent for a wearable device to be prefilled, preloaded, or assembled by the user, defining a clear path for these devices is challenging – but also potentially rewarding.
Register for this webinar, where the speaker will discuss some of the challenges involved in developing a wearable bolus injector. To successfully achieve this, the needs of patients, drug formulators, pharmaceutical manufacturing commercial teams, and the environment must all be carefully balanced, whilst employing established and trusted processes to minimize the barriers to entry for these devices. The speaker will also demonstrate how Phillips-Medisize and Subcuject are engaged to address these challenges with a novel, cost-effective device that requires no battery, motor or electronics.

Last modified: 2021-07-28 17:52:50